ClinicalTrials.gg
Not yet recruitingNCT07949812AFTUpdated Nov 19, 2026

Assessment of Upper Airway Patency

An interventional study of Physiological test in General Population, OSA - Obstructive Sleep Apnea and Obesity Hypoventilation Syndrome (OHS), sponsored by Fisher and Paykel Healthcare. Not yet recruiting at 1 site in New Zealand. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionObesity Hypoventilation SyndromeRegistry: Sleep Apnea, ObstructiveReclassifiedWhy we changed it
Registry
Sleep Apnea, Obstructive — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity Hypoventilation Syndrome
Why
  1. The study's listed conditions name Obesity Hypoventilation Syndrome, a narrower term within Sleep Apnea, Obstructive.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fisher and Paykel Healthcare · Not applicable, Interventional, and Basic science

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This investigation aims to assess upper airway patency in the general population and on people who currently receive respiratory therapies, using differential pressure delivery to the mouth and nose. Tests will be conducted on volunteers using a range of pressure conditions delivered independently to the oral and nasal airways. Baseline participant characteristics, airway measurements, and physiological respiratory parameters will be collected.

02

Conditions studied

  • General Population
  • OSA - Obstructive Sleep Apnea
  • Obesity Hypoventilation Syndrome (OHS)
  • COPD

Keywords

  • upper airway
  • airway patency
  • resistance to flow
03

In context

Obesity Hypoventilation Syndrome Reclassified

74 studies on the registry are indexed under Obesity Hypoventilation Syndrome; 10 are open to participants now.

This study's planned enrollment of 100 is above the median of 40 across 42 interventional studies indexed under Obesity Hypoventilation Syndrome.

Browse Obesity Hypoventilation Syndrome studies →

Lead sponsor

Fisher and Paykel Healthcare is the lead sponsor of 87 studies on the registry; 17 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.

Compared within Obesity Hypoventilation Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sleep Apnea, Obstructive. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18
  • Capacity to complete

Exclusion criteria

Exclusion Criteria:

  1. Acute respiratory illness or self-reported cold/flu symptoms at the time of the study visit(s)
  2. Consider themselves unable to wear a facemask for two hours e.g. they may suffer from claustrophobia or can't tolerate something over/on their face for two hours
  3. Have had surgery on their stomach, esophagus face, nose, sinuses, throat or any other part of the upper airway
  4. Have had any significant bleeding of the stomach, esophagus, face, nose, sinuses, throat or any other part of the upper airway
  5. Have had a tumour, polyps or malformation in the upper airway
  6. Have had a broken nose
  7. Have had a collapsed lung (pneumothorax)
  8. The test masks do not fit (will be checked prior to consent)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Airway resistance and flow

    Airway resistance and flow

    Other: Physiological test

Interventions

  • OtherPhysiological test

    100 Participants will undergo an airway resistance test and an airway flow test. People identified as having a patent airway will then be invited to take part in an additional airway flow test.

06

What researchers measure

Primary outcomes

  1. Range of airway resistance

    Airway resistance when on continuous positive airway pressure (CPAP)

    Time frame: 30 minutes

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The data will be used to inform future research and development.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 17 interventional studies with no phase under Obesity Hypoventilation Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949812
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Joanne E Lorimer, PhD Biochemistry
Contact
joanne.lorimer@fphcare.co.nz
+6421363446
Lotte van den Heuij, PhD Physiology
Contact
Lotte.VandenHeuij@fphcare.co.nz
+64210624848
William Good, MD
principal investigator · Middlemore Hospital, New Zealand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion